IN THIS SECTION: ALSO In this section:
4 Months to <2 Years 6 Years or Older 12 Years or Older

Clinical Trials for Ages 2 to <6 Years
TRIAL 6 (KIWI): Patients with CF age 2 to less than 6 years. KALYDECO® (ivacaftor): Safety consistent with patients age 6 years and older1,2

ON THIS PAGE: Study Design | Summary of Results

 

Mutations Eligible for Study2 (mutations in bold were enrolled)
G551D, G1244E, G1349D, G178R, G551S, G970R*, S1251N, S1255P, S549N, or S549R


*KALYDECO is not indicated for use in patients with a G970R mutation1


STUDY DESIGN1,2

  • Trial 6 was a 24-week, open-label trial (N=34) evaluating safety, pharmacokinetics, and pharmacodynamics in patients with CF age 2 to less than 6 years (mean age: 3 years)1
    • Patients were eligible if they had either a G551D, G1244E, G1349D, G178R, G551S, G970R*, S1251N, S1255P, S549N, or S549R mutation2
    • Of the 34 patients enrolled, 32 had the G551D mutation and 2 had the S549N mutation2
  • Patients received KALYDECO every 12 hours with fat-containing food, in addition to their prescribed CF therapies, based on weight; 7 kg to <14 kg: One 50-mg packet of oral granules; ≥14 kg: One 75-mg packet of oral granules2

 

Primary outcome2: Safety, assessed by adverse events and clinical laboratory assessments

Select secondary outcome measure2: Absolute change from baseline in sweat chloride concentration at 24 weeks

 

Trial 6 limitations2

  • The study was open label and not placebo controlled; therefore, causality cannot be attributed
  • All patients in the study knew they were on active drug, which may have introduced a treatment bias

     

    SUMMARY OF RESULTS1

    Safety results and pharmacokinetics were similar to older patients1

    • The safety profile for patients in Trial 6, including type and frequency of adverse reactions, was similar to that observed in Trials 1 and 2
    • Transaminase elevations were more common in patients who had abnormal transaminases at baseline
      • The incidence of patients experiencing transaminase elevations (ALT or AST) >3x ULN was 14.7% (5/34). All 5 patients had maximum ALT or AST levels >8x ULN, which returned to baseline levels following interruption of KALYDECO dosing. KALYDECO was permanently discontinued in 1 patient
    • Ivacaftor exposure in patients age 2 to less than 6 years administered either 50 mg or 75 mg of KALYDECO oral granules every 12 hours was similar to that observed in older patients administered KALYDECO tablets
    • KALYDECO oral granules (2 x 75 mg) had similar bioavailability as the 150-mg tablet when given with fat-containing food

    The efficacy of KALYDECO in patients age 2 to less than 6 years
    was extrapolated from patients age 6 years and older with support from
    population pharmacokinetic analyses showing similar drug exposure levels in adults and
    children age 2 to less than 6 years.1

    Reduction in sweat chloride from baseline (pharmacodynamic measure) with KALYDECO1,†

     

    trial 6 chart

    †SD 24.3, P=0.002 for patients who received 50 mg; SD 27.6, P<0.0001 for patients who received 75 mg.2

    sweat
    • The mean absolute change from baseline in sweat chloride for patients age 2 to less than 6 years (n=34) was −45 mmol/L (95% CI: −53, −38) through Week 24 (secondary endpoint)1,2
    • There was no direct correlation between decrease in sweat chloride levels and improvement in lung function (FEV1)1

    CI, confidence interval; SD, standard deviation.

    Back to top
    Discover more about the treatment eligibility of KALYDECO
    View the safety profile of KALYDECO